AF
YMAB

Amalgamated Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Amalgamated Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$68K Buy
+5,706
New +$58.6K ﹤0.01% 2280

Other funds holding YMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Amalgamated Financial's YMAB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Y-mAbs Therapeutics (YMAB) in Q1 2022: 5,706 shares worth $68K. The stake represents ﹤0.01% of the portfolio and ranks #2280 among its holdings.

88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

  • Amalgamated Financial held 5,706 shares of Y-mAbs Therapeutics worth $68K as of Q1 2022.
  • Y-mAbs Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Y-mAbs Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2280 holding.
  • 88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.